中国麻风皮肤病杂志 ›› 2024, Vol. 40 ›› Issue (2): 89-94.doi: 10.12144/zgmfskin202402089

• 论著 • 上一篇    下一篇

氘可来昔替尼治疗中重度斑块状银屑病疗效及安全性Meta分析

胥杨1,詹纬生2,赵菊花1   

  1. 1南充市中心医院·川北医学院第二临床医学院皮肤科，四川南充，637000；2川北医学院，四川南充，637000
  • 出版日期:2024-02-15 发布日期:2024-01-30

Efficacy and safety of deucravacitinib in the treatment of moderate-to-severe plaque psoriasis: a meta-analysis

XU Yang1, ZHAN Weisheng2, ZHAO Juhua1   

  1. 1 Department of Dermatology, Nanchong Central Hospital, The Second Clinical Medical College of North Sichuan Medical College, Nanchong 637000, China; 2 North Sichuan Medical College, Nanchong 637000, China
  • Online:2024-02-15 Published:2024-01-30

PDF (PC)

119

摘要： 目的：系统评价氘可来昔替尼治疗中重度斑块状银屑病的疗效及安全性。方法：通过检索PubMed、Cochrane Library、Embase、中国知网、维普、万方数据库及临床试验网站clinicaltrials.gov，筛选出符合要求的随机对照试验（RCT），提取数据后行Meta分析。结果：共纳入4项RCTs，包括1996例中重度斑块状银屑病患者。Meta分析结果显示：治疗16周或12周后氘可来昔替尼组达到各项疗效指标（PASI 75、sPGA 0/1、PASI 90、PASI 100、DLQI 0/1）的患者比例明显高于安慰剂组及阿普米司特组（P<0.05）；治疗24周后氘可来昔替尼组达到各项疗效指标的比例仍明显高于阿普米司特组（P<0.05）；氘可来昔替尼组总的不良事件发生率高于安慰剂组（P<0.05），与阿普米司特组相当（P＞0.05），氘可来昔替尼组严重不良事件发生率与安慰剂组或阿普米司特组无统计学差异（P＞0.05）。结论：氘可来昔替尼治疗斑块状银屑病的疗效优于安慰剂和阿普米司特，且耐受性良好。

关键词: 氘可来昔替尼, 斑块状银屑病, Meta分析

Abstract: Objective: To evaluate the efficacy and safety of deucravacitinib in the treatment of moderate-to-severe plaque psoriasis. Methods: The related literature were searched in Pubmed, Cochrane Library, Embase, CNKI, VIP, Wanfang and clinicaltrials.gov. All randomized controlled trials (RCT) that meet the requirements were collected. Meta-analysis was performed after extracting the data. Results: A total of four RCTs were included,including 1996 patients with moderate-to-severe plaque psoriasis. Meta-analysis showed that the rate of patients in the deucravacitinib group who reached various efficacy indicators (PASI 75, sPGA 0/1, PASI 90, PASI 100, DLQI 0/1) were significantly higher than that in the placebo group or the apremilast group after 16 or 24 weeks of treatment (P<0.05); the rate of patients in the deucravacitinib group who reached various efficacy indicators (PASI 75, sPGA 0/1, PASI 90, PASI 100, DLQI 0/1) were still significantly higher than that in the apremilast group after 24 weeks of treatment (P<0.05). The incidence of total adverse events in the deucravacitinib group was higher than that in the placebo group (P<0.05), which was comparable to the apremilast group (P＞0.05). There was no statistical difference in the incidence of serious adverse events between the deucravacitinib group and the placebo group or the apremilast group (P＞0.05). Conclusion: Deucravacitinib is superior to both placebo and apremilast in treating moderate-to-severe plaque psoriasis, and adverse effects are well tolerated.

Key words: deucravacitinib, plaque psoriasis, meta-analysis